PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta).

Article Details

Citation

Copy to clipboard

Shrestha S, Bhattarai BR, Cho H, Choi JK, Cho H

PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta).

Bioorg Med Chem Lett. 2007 May 15;17(10):2728-30. Epub 2007 Mar 3.

PubMed ID

17407812 [ View in PubMed

]

Abstract

Ertiprotafib was developed as an inhibitor of PTP1B for the treatment of type 2 diabetes. It normalized the plasma glucose and insulin levels in diabetic animal models, and progressed to a phase II clinical trial. Multiple in vivo targets of Ertiprotafib, in addition to PTP1B inhibition, have been suggested. In this study, Ertiprotafib was also shown to be a potent inhibitor of IkappaB kinase beta (IKK-beta), with an IC(50) of 400nM.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Ertiprotafib	Inhibitor of nuclear factor kappa-B kinase subunit beta	Protein	Humans	Unknown	Not Available	Details
Ertiprotafib	Tyrosine-protein phosphatase non-receptor type 1	Protein	Humans	Unknown	Not Available	Details